---
title: "PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297657742.md"
description: "PMV Pharmaceuticals announced interim Phase 2 data for ovarian cancer drug rezatapopt, showing a 46% overall response rate. The company plans to submit a New Drug Application to the FDA in Q1 2027 for accelerated approval. Additionally, PMV raised $50.8 million through a public offering to fund research and regulatory efforts."
datetime: "2026-09-01T13:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297657742.md)
  - [en](https://longbridge.com/en/news/297657742.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297657742.md)
generator: "portal-rs"
---

# PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

**PMV Pharmaceuticals Inc.** (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer.

Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of the drug.

## Efficacy Highlights

The interim data, gathered up to May 14, 2026, focus on patients with platinum-resistant or refractory ovarian cancer bearing the TP53 Y220C mutation.

The trial results demonstrated a 46% overall response rate (ORR) among the 76 patients evaluated. This included four confirmed complete responses and 29 confirmed partial responses.

Rezatapopt also showed a median duration of response of 10.0 months, indicating sustained effectiveness.

The drug’s safety profile remained favorable, primarily presenting Grade 1 and 2 treatment-related adverse events, with a low 5% discontinuation rate linked to these events.

 **Read Also: Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study** 

## Regulatory Path

The company plans to present a comprehensive update on all PYNNACLE Phase 2 cohorts at an upcoming medical conference in the fourth quarter of 2026.

Following a recent FDA meeting, PMV Pharmaceuticals received feedback supporting its strategy to seek accelerated approval for rezatapopt. The company intends to submit the NDA in the first quarter of 2027.

## Funding The Future

In related news, PMV Pharmaceuticals priced a public offering expected to generate approximately $50.8 million in gross proceeds.

The offering includes shares of common stock, pre-funded warrants, and accompanying warrants, with a combined public offering price of $1.21 per share and warrant combination.

The financial move supports the company’s ongoing research and anticipated regulatory submissions.

**PMVP Price Action:** PMV Pharmaceuticals shares were down 10.74% at $1.08 during premarket trading on Tuesday, according to Benzinga Pro data.

*Image via Shutterstock*

 **Read Also: NVIDIA Widens Its AI Moat With MediaTek**

### Related Stocks

- [PMVP.US](https://longbridge.com/en/quote/PMVP.US.md)
- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)
- [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md)
- [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md)

## Related News & Research

- [BUZZ-Oncology firm PMV Pharma falls on $51 mln stock-and-warrants sale](https://longbridge.com/en/news/297642898.md)
- [PMV Pharma says rezatapopt posts 46% response rate in Phase 2 platinum-resistant ovarian cancer trial](https://longbridge.com/en/news/297555827.md)
- [Micron introduces quarterly employee bonus tied to profits](https://longbridge.com/en/news/302675659.md)
- [TTM Technologies Q3 net income jumps 60% to $84.8 million; Q3 net sales rise 60% to $1.2 billion](https://longbridge.com/en/news/302693400.md)
- [SpaceX Bulls Get Louder After Q3 Earnings Print, But One Firm Flags $475B Funding Gap](https://longbridge.com/en/news/302596793.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**